Cardiometabolic Response to a Sodium-bicarbonated Mineral Water
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy adults, men and women >18 and ≤ 45 years
- Total-cholesterol > 200 mg/dL and < 300 mg/dL
Exclusion Criteria:
- Age <18 and > 45 years
- Total-cholesterol ≥300 mg/dL
- Triglycerides > 250 mg/dL
- Total-cholesterol / HDL-cholesterol > 6
- Being a usual consumer of carbonic mineral water
- BMI < 20 and >30 kg/m2
- Diabetes
- Hypertension or digestive, liver or renal disease
- Eating disorders
- Being under medication that could affect lipid metabolism
- Consumption of functional foods that could affect lipid metabolism (food containing n-3 fatty acids or phytosterols)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: SINGLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Bicarbonated mineral water (BW)
Bicarbonated mineral water
|
Intake of 1 L per day of the mineral water (BW or CW) with main meals, crossover design
|
|
Active Comparator: Control mineral water (CW)
Mineral water low in mineral content (control)
|
Intake of 1 L per day of the mineral water (BW or CW) with main meals, crossover design
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
LDL-cholesterol
Time Frame: 8 weeks
|
8 weeks
|
|
LDL-cholesterol
Time Frame: Baseline
|
Baseline
|
|
LDL-cholesterol
Time Frame: 4 weeks
|
4 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Triglycerides
Time Frame: 8 weeks
|
8 weeks
|
|
HDL-cholesterol
Time Frame: 8 weeks
|
8 weeks
|
|
Systolic Blood Pressure
Time Frame: 8 weeks
|
8 weeks
|
|
Systolic Blood Pressure
Time Frame: Baseline
|
Baseline
|
|
Diastolic Blood Pressure
Time Frame: Baseline
|
Baseline
|
|
BMI
Time Frame: 8 weeks
|
8 weeks
|
|
BMI
Time Frame: Baseline
|
Baseline
|
|
Oxidized LDL
Time Frame: 8 weeks
|
8 weeks
|
|
Insulin
Time Frame: 8 weeks
|
8 weeks
|
|
Glucose
Time Frame: 8 weeks
|
8 weeks
|
|
Insulin
Time Frame: 4 weeks
|
4 weeks
|
|
Triglycerides
Time Frame: 4 weeks
|
4 weeks
|
|
Systolic Blood Pressure
Time Frame: 4 weeks
|
4 weeks
|
|
Diastolic Blood Pressure
Time Frame: 4 weeks
|
4 weeks
|
|
BMI
Time Frame: 4 weeks
|
4 weeks
|
|
HDL-cholesterol
Time Frame: Baseline
|
Baseline
|
|
HDL-cholesterol
Time Frame: 4 weeks
|
4 weeks
|
|
Apolipoprotein B
Time Frame: 4 weeks
|
4 weeks
|
|
Total-cholesterol
Time Frame: Baseline
|
Baseline
|
|
Total-cholesterol
Time Frame: 4 weeks
|
4 weeks
|
|
Total-cholesterol
Time Frame: 8 weeks
|
8 weeks
|
|
Triglycerides
Time Frame: Baseline
|
Baseline
|
|
Apolipoprotein A
Time Frame: Baseline
|
Baseline
|
|
Apolipoprotein A
Time Frame: 4 weeks
|
4 weeks
|
|
Apolipoprotein A
Time Frame: 8 weeks
|
8 weeks
|
|
Apolipoprotein B
Time Frame: Baseline
|
Baseline
|
|
Apolipoprotein B
Time Frame: 8 weeks
|
8 weeks
|
|
Glucose
Time Frame: Baseline
|
Baseline
|
|
Glucose
Time Frame: 4 weeks
|
4 weeks
|
|
Insulin
Time Frame: Baseline
|
Baseline
|
|
Urine creatinin
Time Frame: Baseline
|
Baseline
|
|
Urine creatinin
Time Frame: 8 weeks
|
8 weeks
|
|
Urine calcium
Time Frame: Baseline
|
Baseline
|
|
Urine calcium
Time Frame: 8 weeks
|
8 weeks
|
|
Urine potassium
Time Frame: Baseline
|
Baseline
|
|
Urine potassium
Time Frame: 8 weeks
|
8 weeks
|
|
Urine sodium
Time Frame: Baseline
|
Baseline
|
|
Urine sodium
Time Frame: 8 weeks
|
8 weeks
|
|
Urine pH
Time Frame: Baseline
|
Baseline
|
|
Urine pH
Time Frame: 8 weeks
|
8 weeks
|
|
Diastolic Blood Pressure
Time Frame: 8 weeks
|
8 weeks
|
|
Oxidized LDL
Time Frame: Baseline
|
Baseline
|
|
Oxidized LDL
Time Frame: 4 weeks
|
4 weeks
|
|
Serum aldosterone
Time Frame: Baseline
|
Baseline
|
|
Serum aldosterone
Time Frame: 8 weeks
|
8 weeks
|
|
Dietary energy intake
Time Frame: Baseline
|
Baseline
|
|
Dietary energy intake
Time Frame: 8 weeks
|
8 weeks
|
|
Dietary protein intake
Time Frame: Baseline
|
Baseline
|
|
Dietary protein intake
Time Frame: 8 weeks
|
8 weeks
|
|
Dietary fat intake
Time Frame: Baseline
|
Baseline
|
|
Dietary fat intake
Time Frame: 8 weeks
|
8 weeks
|
|
Dietary cholesterol intake
Time Frame: Baseline
|
Baseline
|
|
Dietary cholesterol intake
Time Frame: 8 weeks
|
8 weeks
|
|
Dietary carbohydrate intake
Time Frame: Baseline
|
Baseline
|
|
Dietary carbohydrate intake
Time Frame: 8 weeks
|
8 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- BW-13
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dyslipidemia
-
NCT02066207CompletedDyslipidemia (Fredrickson Type Ⅱa) | Dyslipidemia (Fredrickson Type Ⅱb)
-
NCT01256476CompletedMixed Dyslipidemia | Primary Dyslipidemia
-
NCT07394517Not yet recruitingMixed Dyslipidemia
-
NCT07152873Not yet recruiting
-
NCT07319559Completed
-
NCT06932705Recruiting
-
NCT06204380Recruiting
-
NCT03648788Not yet recruiting
-
NCT04998201CompletedMixed Dyslipidemia
Clinical Trials on Mineral water
-
NCT07005375Enrolling by invitationLow Back Pain | Performance Measures | Fatigue Recovery
-
NCT04282512Completed
-
NCT02444975Completed
-
NCT02641912Completed
-
NCT05375487Completed
-
NCT03005041Completed
-
NCT07211113CompletedMASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease